phase 1_2_initiation
saveNational Cancer Institute US — sacituzumab govitecan (Phase I/II Trial Initiation)
community read0 votes
Therapy area: Oncology. Indication: Neuroendocrine Cancer, Neuroendocrine Carcinoma, Small-Cell Lung Cancer
Data sources
globaldata
Found something off?
same company · ±60 days · 6
- phase 2 initiationcyclophosphamide: National Cancer Institute US — cyclophosphamide (Phase II Trial Initiation)Apr 27, 2026
- phase 1 initiationAutologous B7-H3 CAR T: National Cancer Institute US — Autologous B7-H3 CAR T (Phase I Trial Initiation)Apr 27, 2026
- phase 2 initiationbusulfan: National Cancer Institute US — busulfan (Phase II Trial Initiation)Apr 27, 2026
- phase 1 completionundisclosed chemotherapy: National Cancer Institute US — undisclosed chemotherapy (Phase I Trial Completion)Apr 28, 2026
- phase 2 initiation(daratumumab + hyaluronidase (human recombinant)): National Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)Apr 29, 2026
- phase 2 completionipilimumab: National Cancer Institute US — ipilimumab (Phase II Trial Completion)Apr 30, 2026
related news · 8
- oncliveHonesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond
- oncliveGU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
- oncliveDr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma
- oncliveMimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors
- oncliveDr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCT
- oncliveExpanding ctDNA Applications to RCC and Germ Cell Tumors
- oncliveRenal Cell Carcinoma: Real-World Factors in First-Line Treatment Selection
- oncliveRAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practice
comments(0)
5-min edit window · permanent after that